{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:39:43Z","timestamp":1790962783262,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.numecd.2021.12.006","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T20:56:37Z","timestamp":1639083397000},"page":"529-536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Effects of pioglitazone on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9759-9408","authenticated-orcid":false,"given":"Edoardo","family":"Mannucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7462-7792","authenticated-orcid":false,"given":"Andrea","family":"Giaccari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7166-0848","authenticated-orcid":false,"given":"Marco","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-3900","authenticated-orcid":false,"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basilio","family":"Pintaudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Candido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9349-828X","authenticated-orcid":false,"given":"Matteo","family":"Monami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.numecd.2021.12.006_bib1","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"issue":"7258","key":"10.1016\/j.numecd.2021.12.006_bib2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.numecd.2021.12.006_bib3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.numecd.2019.07.018","article-title":"Exploring the heterogeneity of the effects of SGLT-2 inhibitors in cardiovascular outcome trials","volume":"30","author":"Mannucci","year":"2020","journal-title":"Nutr Metabol Cardiovasc Dis : Nutr Metabol Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.numecd.2021.12.006_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00592-016-0892-7","article-title":"Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials","volume":"54","author":"Monami","year":"2017","journal-title":"Acta Diabetol"},{"issue":"5","key":"10.1016\/j.numecd.2021.12.006_bib5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis","volume":"4","author":"Wu","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.numecd.2021.12.006_bib6","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.numecd.2020.03.013","article-title":"Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials","volume":"30","author":"Nreu","year":"2020","journal-title":"Nutr Metabol Cardiovasc Dis : Nutr Metabol Cardiovasc Dis"},{"issue":"17","key":"10.1016\/j.numecd.2021.12.006_bib7","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.numecd.2021.12.006_bib8","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2337\/diabetes.53.6.1621","article-title":"Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes","volume":"53","author":"Tonelli","year":"2004","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.numecd.2021.12.006_bib9","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2337\/diacare.24.4.710","article-title":"Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone","volume":"24","author":"Miyazaki","year":"2001","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.numecd.2021.12.006_bib10","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1210\/jc.2004-0190","article-title":"Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients","volume":"89","author":"Miyazaki","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.numecd.2021.12.006_bib11","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1177\/193229681100500422","article-title":"Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study","volume":"5","author":"Pf\u00fctzner","year":"2011","journal-title":"J Diabetes Sci Technol"},{"issue":"12","key":"10.1016\/j.numecd.2021.12.006_bib12","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2005.03.041","article-title":"Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study","volume":"45","author":"Pf\u00fctzner","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.numecd.2021.12.006_bib13","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc06-1854","article-title":"Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: a meta-analysis","volume":"30","author":"Riche","year":"2007","journal-title":"Diabetes Care"},{"issue":"9493","key":"10.1016\/j.numecd.2021.12.006_bib14","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.numecd.2021.12.006_bib15","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials","volume":"298","author":"Lincoff","year":"2007","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.numecd.2021.12.006_bib16","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/j.1463-1326.2008.00892.x","article-title":"Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials","volume":"10","author":"Mannucci","year":"2008","journal-title":"Diabetes Obes Metabol"},{"issue":"6","key":"10.1016\/j.numecd.2021.12.006_bib17","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/MJT.0b013e318167180c","article-title":"Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials","volume":"15","author":"Nagajothi","year":"2008","journal-title":"Am J Therapeut"},{"issue":"1","key":"10.1016\/j.numecd.2021.12.006_bib18","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12933-017-0617-4","article-title":"Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials","volume":"16","author":"de Jong","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"10.1016\/j.numecd.2021.12.006_bib19","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz252","article-title":"Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis","volume":"105","author":"Zhou","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.numecd.2021.12.006_bib20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","article-title":"GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.numecd.2021.12.006_bib21","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.numecd.2021.12.006_bib22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1463-1326.2008.01023.x","article-title":"Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin","volume":"11","author":"Bolli","year":"2009","journal-title":"Diabetes Obes Metabol"},{"issue":"12","key":"10.1016\/j.numecd.2021.12.006_bib23","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1463-1326.2011.01463.x","article-title":"Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study","volume":"13","author":"Bosi","year":"2011","journal-title":"Diabetes Obes Metabol"},{"issue":"7","key":"10.1016\/j.numecd.2021.12.006_bib24","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2337\/diacare.27.7.1647","article-title":"The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients","volume":"27","author":"Charbonnel","year":"2004","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.numecd.2021.12.006_bib25","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00125-005-1751-1","article-title":"Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes","volume":"48","author":"Charbonnel","year":"2005","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.numecd.2021.12.006_bib26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2169\/internalmedicine.48.1670","article-title":"Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine","volume":"48","author":"Derosa","year":"2009","journal-title":"Intern Med"},{"issue":"3","key":"10.1016\/j.numecd.2021.12.006_bib27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1751-7133.2010.00154.x","article-title":"Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease","volume":"16","author":"Giles","year":"2010","journal-title":"Congest Heart Fail"},{"issue":"3","key":"10.1016\/j.numecd.2021.12.006_bib28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/dom.12194","article-title":"Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial study","volume":"16","author":"Henry","year":"2014","journal-title":"Diabetes Obes Metabol"},{"issue":"2","key":"10.1016\/j.numecd.2021.12.006_bib29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/dom.12414","article-title":"Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1yearin people with type 2 diabetes currently taking metformin and glimepiride\u202f:HARMONY 5","volume":"17","author":"Home","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.numecd.2021.12.006_bib30","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1592\/phco.26.10.1388","article-title":"Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus","volume":"26","author":"Jain","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"7","key":"10.1016\/j.numecd.2021.12.006_bib31","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s40618-018-0991-0","article-title":"Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea","volume":"42","author":"Khaloo","year":"2019","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"10.1016\/j.numecd.2021.12.006_bib32","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3349\/ymj.2013.54.6.1313","article-title":"Effects of low dose pioglitazone on restenosis and coronary atherosclerosis in diabetic patients undergoing drug eluting stent implantation","volume":"54","author":"Lee","year":"2013","journal-title":"Yonsei Med J"},{"issue":"2","key":"10.1016\/j.numecd.2021.12.006_bib33","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/dmrr.478","article-title":"Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study","volume":"21","author":"Matthews","year":"2005","journal-title":"Diabetes Metab Res Rev"},{"issue":"21","key":"10.1016\/j.numecd.2021.12.006_bib34","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","article-title":"Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial","volume":"296","author":"Mazzone","year":"2006","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.numecd.2021.12.006_bib35","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","article-title":"Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.numecd.2021.12.006_bib36","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3132\/dvdr.2007.044","article-title":"Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetes","volume":"4","author":"Perriello","year":"2007","journal-title":"Diabetes Vasc Dis Res"},{"issue":"12","key":"10.1016\/j.numecd.2021.12.006_bib37","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1210\/jc.2003-030861","article-title":"Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial","volume":"89","author":"Schernthaner","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.numecd.2021.12.006_bib38","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1185\/030079904125003386","article-title":"Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes","volume":"20","author":"Tan","year":"2004","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"10.1016\/j.numecd.2021.12.006_bib39","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1464-5491.2004.01258.x","article-title":"Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes","volume":"21","author":"Tan","year":"2004","journal-title":"Diabet Med"},{"issue":"5","key":"10.1016\/j.numecd.2021.12.006_bib40","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0149-2918(04)90068-9","article-title":"Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, parallel-group trial","volume":"26","author":"Tan","year":"2004","journal-title":"Clin Therapeut"},{"issue":"9","key":"10.1016\/j.numecd.2021.12.006_bib41","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2165\/11316510-000000000-00000","article-title":"Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US","volume":"32","author":"Tolman","year":"2009","journal-title":"Drug Saf"},{"issue":"11","key":"10.1016\/j.numecd.2021.12.006_bib42","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S2213-8587(17)30317-0","article-title":"Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial","volume":"5","author":"Vaccaro","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.numecd.2021.12.006_bib43","first-page":"563","article-title":"Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study","volume":"21","author":"Yoshii","year":"2014","journal-title":"J Atherosclerosis Thromb"},{"issue":"11","key":"10.1016\/j.numecd.2021.12.006_bib44","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.5551\/jat.4663","article-title":"Long-term effects of pioglitazone on carotid atherosclerosis in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity","volume":"17","author":"Yamasaki","year":"2010","journal-title":"J Atherosclerosis Thromb"},{"issue":"2","key":"10.1016\/j.numecd.2021.12.006_bib45","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1479164118825376","article-title":"Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes","volume":"16","author":"DeFronzo","year":"2019","journal-title":"Diabetes Vasc Dis Res"},{"issue":"8","key":"10.1016\/j.numecd.2021.12.006_bib46","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1463-1326.2009.01048.x","article-title":"The role of pioglitazone in modifying the atherogenic lipoprotein profile","volume":"11","author":"Hanefeld","year":"2009","journal-title":"Diabetes Obes Metabol"},{"issue":"1","key":"10.1016\/j.numecd.2021.12.006_bib47","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1161\/01.ATV.0000195790.24531.4f","article-title":"Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome","volume":"26","author":"Szapary","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.numecd.2021.12.006_bib48","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jcin.2009.04.007","article-title":"A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study)","volume":"2","author":"Takagi","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"10.1016\/j.numecd.2021.12.006_bib49","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1016\/S0002-8703(03)00146-7","article-title":"Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study","volume":"146","author":"Takagi","year":"2003","journal-title":"Am Heart J"},{"issue":"12","key":"10.1016\/j.numecd.2021.12.006_bib50","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.2337\/dc12-0954","article-title":"The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes","volume":"35","author":"Vaccaro","year":"2012","journal-title":"Diabetes Care"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475321005652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475321005652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:20:22Z","timestamp":1760545222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475321005652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0939475321005652"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2021.12.006","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of pioglitazone on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2021.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}